AIMS: The aim of our study was to develop and optimize methods for relative and absolute protein quantifications in formalin-fixed and paraffin-embedded (FFPE) tissues with special emphasis on HER mediated pathways in breast cancer. METHODS: Using a recently developed technology for extraction of full-length proteins from FFPE tissues, we evaluated >50 commercial antibodies for specificity using Western blots and protein microarrays. Purified HER receptor proteins were used to determine absolute protein concentrations. RESULTS: We confirmed specificity of 23 commercially available phosphospecific and non-phosphospecific antibodies using Western blots with protein extracts from cell lines and tissue extracts from breast cancer patients. Spiking known amounts of purified HER receptor proteins in HER receptor negative tissue extracts allowed us to precisely measure abundances of HER-receptors. CONCLUSIONS: Our results will provide a basis for the development of diagnostic techniques for the quantitative analysis of deregulated HER receptors and downstream signalling proteins in typical clinical tissues.
AIMS: The aim of our study was to develop and optimize methods for relative and absolute protein quantifications in formalin-fixed and paraffin-embedded (FFPE) tissues with special emphasis on HER mediated pathways in breast cancer. METHODS: Using a recently developed technology for extraction of full-length proteins from FFPE tissues, we evaluated >50 commercial antibodies for specificity using Western blots and protein microarrays. Purified HER receptor proteins were used to determine absolute protein concentrations. RESULTS: We confirmed specificity of 23 commercially available phosphospecific and non-phosphospecific antibodies using Western blots with protein extracts from cell lines and tissue extracts from breast cancerpatients. Spiking known amounts of purified HER receptor proteins in HER receptor negative tissue extracts allowed us to precisely measure abundances of HER-receptors. CONCLUSIONS: Our results will provide a basis for the development of diagnostic techniques for the quantitative analysis of deregulated HER receptors and downstream signalling proteins in typical clinical tissues.
Authors: Lance A Liotta; Virginia Espina; Arpita I Mehta; Valerie Calvert; Kevin Rosenblatt; David Geho; Peter J Munson; Lynn Young; Julia Wulfkuhle; Emanuel F Petricoin Journal: Cancer Cell Date: 2003-04 Impact factor: 31.743
Authors: Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau Journal: Mol Cancer Ther Date: 2006-10 Impact factor: 6.261
Authors: K Ikeda; T Monden; T Kanoh; M Tsujie; H Izawa; A Haba; T Ohnishi; M Sekimoto; N Tomita; H Shiozaki; M Monden Journal: J Histochem Cytochem Date: 1998-03 Impact factor: 2.479
Authors: Emanuel F Petricoin; Verena E Bichsel; Valerie S Calvert; Virginia Espina; Mary Winters; Lynn Young; Claudio Belluco; Bruce J Trock; Marc Lippman; David A Fishman; Dennis C Sgroi; Peter J Munson; Laura J Esserman; Lance A Liotta Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Joon-Yong Chung; Seo-Jin Lee; Ylaya Kris; Till Braunschweig; June L Traicoff; Stephen M Hewitt Journal: Proteomics Clin Appl Date: 2008-08-26 Impact factor: 3.494
Authors: Katherine M Sheehan; Valerie S Calvert; Elaine W Kay; Yiling Lu; David Fishman; Virginia Espina; Joy Aquino; Runa Speer; Robyn Araujo; Gordon B Mills; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle Journal: Mol Cell Proteomics Date: 2005-01-25 Impact factor: 5.911